Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
8.94 +0.19 (+2.17%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 9.07 +0.13 (+1.45%) 19:04 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.61
Day High
9.05
Open 8.87
Previous Close 8.75 8.75
Volume 2,383,700 2,383,700
Avg Vol 2,789,465 2,789,465
Stochastic %K 96.86% 96.86%
Weighted Alpha -52.06 -52.06
5-Day Change +1.54 (+20.81%) +1.54 (+20.81%)
52-Week Range 5.93 - 37.38 5.93 - 37.38
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 601,755
  • Shares Outstanding, K 68,772
  • Annual Sales, $ 263,400 K
  • Annual Income, $ -198,900 K
  • EBIT $ -250 M
  • EBITDA $ -261 M
  • 60-Month Beta 2.30
  • Price/Sales 2.25
  • Price/Cash Flow N/A
  • Price/Book 1.05

Options Overview Details

View History
  • Implied Volatility 73.06% ( +2.03%)
  • Historical Volatility 226.22%
  • IV Percentile 31%
  • IV Rank 11.61%
  • IV High 218.75% on 02/10/25
  • IV Low 53.93% on 03/28/25
  • Put/Call Vol Ratio 0.37
  • Today's Volume 2,092
  • Volume Avg (30-Day) 2,991
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 51,330
  • Open Int (30-Day) 74,474

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.86
  • Number of Estimates 10
  • High Estimate -0.51
  • Low Estimate -1.24
  • Prior Year -0.97
  • Growth Rate Est. (year over year) +11.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.93 +50.76%
on 04/09/25
Period Open: 8.75
9.05 -1.22%
on 04/22/25
+0.19 (+2.17%)
since 03/21/25
3-Month
5.93 +50.76%
on 04/09/25
Period Open: 18.22
20.38 -56.13%
on 02/18/25
-9.28 (-50.93%)
since 01/22/25
52-Week
5.93 +50.76%
on 04/09/25
Period Open: 34.90
37.38 -76.08%
on 05/22/24
-25.96 (-74.38%)
since 04/22/24

Most Recent Stories

More News
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

ARVN : 8.94 (+2.17%)
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

ARVN : 8.94 (+2.17%)
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

ARVN : 8.94 (+2.17%)
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

ARVN : 8.94 (+2.17%)
PFE : 22.53 (+2.22%)
Arvinas to Participate in Upcoming Investor Conferences

ARVN : 8.94 (+2.17%)
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ARVN : 8.94 (+2.17%)
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

ARVN : 8.94 (+2.17%)
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopharmaceutical...

NVDA : 98.89 (+2.04%)
ARVN : 8.94 (+2.17%)
RXRX : 5.63 (+4.07%)
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

ARVN : 8.94 (+2.17%)
Arvinas and Pfizer Announce Encouraging Preliminary Phase 1b Results for Vepdegestrant Combined with Abemaciclib in Advanced ER+/HER2- Breast Cancer

Vepdegestrant combined with abemaciclib shows promising clinical activity and a favorable safety profile in advanced breast cancer patients.Quiver AI SummaryArvinas, Inc. and Pfizer Inc. announced promising...

ARVN : 8.94 (+2.17%)

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 9.56
2nd Resistance Point 9.31
1st Resistance Point 9.12
Last Price 8.94
1st Support Level 8.68
2nd Support Level 8.43
3rd Support Level 8.24

See More

52-Week High 37.38
Fibonacci 61.8% 25.37
Fibonacci 50% 21.66
Fibonacci 38.2% 17.94
Last Price 8.94
52-Week Low 5.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro